SCHEMBL3000602

SCHEMBL3000602

COc1cc(OC)cc(-c2csc(N3CCC(S(=O)(=O)c4c(F)c(F)c(F)c(F)c4F)CC3)n2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.48
HSD17B10 Q99714 3/20 0.48
USP2 O75604 1/20 0.48
RECQL P46063 1/20 0.48
SMN1; SMN2 Q16637 6/20 0.48
RAB9A P51151 4/20 0.48
ALDH1A1 P00352 8/20 0.44
MAPK1 P28482 7/20 0.44
LMNA P02545 7/20 0.44
TP53 P04637 3/20 0.44
TSHR P16473 1/20 0.44
NPC1 O15118 3/20 0.44
HTT P42858 3/20 0.42
GAA P10253 2/20 0.42
HPGD P15428 1/20 0.41
CYP1A1 P04798 1/20 0.41
CYP1B1 Q16678 1/20 0.41
KMT2A Q03164 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017164 0.90 MAPT (0.61) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3006478 0.90 SMN1; SMN2 (0.60) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3008347 0.89 MAPT (0.53) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3008133 0.88 MAPK1 (0.58) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3005648 0.87 SMN1; SMN2 (0.47) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3016543 0.87 SMN1; SMN2 (0.47) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3010762 0.86 SMN1; SMN2 (0.45) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3016018 0.86 SMN1; SMN2 (0.47) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3016011 0.86 MAPT (0.61) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL2998517 0.85 SMN1; SMN2 (0.59) MAPTHSD17B10USP2RECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.